Secondary Logo

Journal Logo

Correspondence

Efavirenz and cognition that matters

Brouillette, Marie-Joséea,b; Fellows, Lesley K.c,d; Mayo, Nancy E.b,e

Author Information
doi: 10.1097/QAD.0000000000002545
  • Free

We read with interest the publication from the SWEAR study group on the neurocognitive impact of switching away from an efavirenz (EFV)-containing regimen [1]. Cognitive difficulties are prevalent in persons living with HIV and have important consequences for function and quality of life. Any approach that might reduce the negative impact of antiretrovirals on cognition should be welcomed. In this context, the study from the SWEAR group is clinically important.

Central Nervous System (CNS) side effects have been reported with EFV and may be a reason for early discontinuation. For those remaining on EFV and who are impaired on cognitive testing, this study tested whether switching from EFV to rilpivirine would improve cognition. A finding from the SWEAR study was that patients who were switched away from EFV reported less frequent cognitive difficulties after 24 weeks (change of −8.81 on 100) than those continuing with this medication (change of −3.79 on 100). The change in the switch group was likely clinically relevant given the SD at baseline was 11.11 (effect size >0.5 SD, 0.79), whereas the change in the continuation group was less than 0.5 SD with an effect size of 0.26. In contrast to this subjective improvement, there were no important changes observed on a battery of cognitive tests. Broadly similar findings were reported in another recent study on this topic [2].

The authors conclude: ‘… our results show that switching from EFV to rilpivirine was not associated with neurocognitive improvement and suggest that the decision to discontinue tenofovir disoproxil fumarate/emtricitabine/EFV among otherwise healthy individuals should not be driven by the expectation of a cognitive improvement following the switch, because it is unlikely to occur’.

The conclusion echoes the current emphasis on performance-based cognition in the neuro-HIV literature. Self-perceived cognition is either not systematically documented or relegated to a secondary outcome. This is unfortunate given the key importance patients place on self-perceived cognition, but also its established role in explaining function and quality of life. Indeed, in our prospective Canadian study (N = 856) [3], self-perceived cognition was a stronger predictor of work status, work productivity, social function, health perception and quality of life than performance-based cognition [4–6].

The discrepancy between impairment on cognitive testing and self-perceived cognition is well known [7–9]. Both are important sources of information about how the patient is doing. Self-reports may more closely reflect real-world difficulties [7]. Our interpretation of this emerging literature is that switching away for EFV may in fact yield real-world benefits to the patient. Further documentation of the impact of this change on measured and self-perceived cognition, as well as on function and quality of life, is warranted.

Acknowledgements

Conflicts of interest

There are no conflicts of interest.

References

1. Lapadula G, Bernasconi DP, Bai F, Foca E, Di Biagio A, Bonora S, et al. Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances. AIDS 2020; 34:53–61.
2. Hakkers CS, Arends JE, van den Berk GE, Ensing MHM, Hooijenga I, Vink M, et al. Objective and subjective improvement of cognition. After discontinuing efavirenz in asymptomatic patients: a randomized controlled trial. J Acquir Immune Defic Syndr 2019; 80:e14–e22.
3. Mayo NE, Brouillette MJ, Fellows LK. Understanding and optimizing brain health in HIV now: protocol for a longitudinal cohort study with multiple randomized controlled trials. BMC Neurol 2016; 16:8.
4. Brouillette M-J, Fellows L, Brew B, Koski L, Cysique L, N. M. Head-to-head comparison of classifications of cognitive impairment for explaining presenteism among HIV+ workers in the Positive Brain Health Now (PBHN) aging Canadian cohort In: 10th International Workshop on HIV & Aging New-York, NY, USA; 2019.
5. Brouillette M-J, Fellows L, Harris M, Smaill F, Smith G, Thomas R, et al. CSP11.01. Impact of Brain Health on Work Status and Productivity in People with HIV. In: The 28th Annual Canadian Conference on HIV/AIDS Research. Saskatoon, Saskatchewan, Canada; 2019.
6. Mayo NE, Brouillette MJ, Scott SC, Harris M, Smaill F, Smith G, et al. Relationships between cognition, function, and quality of life among HIV+ Canadian men. Qual Life Res 2020; 29:37–55.
7. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004; 10:317–331.
8. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24:1243–1250.
9. Bassel C, Rourke SB, Halman MH, Smith ML. Working memory performance predicts subjective cognitive complaints in HIV infection. Neuropsychology 2002; 16:400–410.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.